ATE254138T1 - An den erythropoietin-rezeptor bindende zusammensetzungen und peptide - Google Patents

An den erythropoietin-rezeptor bindende zusammensetzungen und peptide

Info

Publication number
ATE254138T1
ATE254138T1 AT96919296T AT96919296T ATE254138T1 AT E254138 T1 ATE254138 T1 AT E254138T1 AT 96919296 T AT96919296 T AT 96919296T AT 96919296 T AT96919296 T AT 96919296T AT E254138 T1 ATE254138 T1 AT E254138T1
Authority
AT
Austria
Prior art keywords
hoc
peptides
amino
erythropoietin receptor
receptor binding
Prior art date
Application number
AT96919296T
Other languages
English (en)
Inventor
Nicholas C Wrighton
William J Dower
Ray S Chang
Arun K Kashyap
Linda K Jolliffe
Dana Johnson
Linda Mulcahy
Original Assignee
Ortho Pharma Corp
Affymax Tech Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/484,631 external-priority patent/US5830851A/en
Priority claimed from US08/484,635 external-priority patent/US5773569A/en
Application filed by Ortho Pharma Corp, Affymax Tech Nv filed Critical Ortho Pharma Corp
Application granted granted Critical
Publication of ATE254138T1 publication Critical patent/ATE254138T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96919296T 1995-06-07 1996-06-07 An den erythropoietin-rezeptor bindende zusammensetzungen und peptide ATE254138T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/484,631 US5830851A (en) 1993-11-19 1995-06-07 Methods of administering peptides that bind to the erythropoietin receptor
US08/484,635 US5773569A (en) 1993-11-19 1995-06-07 Compounds and peptides that bind to the erythropoietin receptor
PCT/US1996/009810 WO1996040749A1 (en) 1995-06-07 1996-06-07 Compounds and peptides that bind to the erythropoietin receptor

Publications (1)

Publication Number Publication Date
ATE254138T1 true ATE254138T1 (de) 2003-11-15

Family

ID=27048076

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919296T ATE254138T1 (de) 1995-06-07 1996-06-07 An den erythropoietin-rezeptor bindende zusammensetzungen und peptide

Country Status (18)

Country Link
EP (2) EP0886648B8 (de)
JP (3) JP4050314B2 (de)
KR (1) KR100459984B1 (de)
CN (1) CN1192748A (de)
AT (1) ATE254138T1 (de)
AU (1) AU712713B2 (de)
BR (1) BR9609006A (de)
CA (1) CA2223833C (de)
CZ (1) CZ391097A3 (de)
DE (1) DE69630708T2 (de)
ES (1) ES2210374T3 (de)
HU (1) HUP9901069A2 (de)
IL (1) IL122417A0 (de)
NO (1) NO318783B1 (de)
NZ (1) NZ310804A (de)
PL (1) PL185040B1 (de)
TR (1) TR199701557T2 (de)
WO (1) WO1996040749A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) * 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
DE19904396A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolbenzylamin-Derivate
DE19904406A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolcarbonsäuren
US6713309B1 (en) 1999-07-30 2004-03-30 Large Scale Proteomics Corporation Microarrays and their manufacture
US7179638B2 (en) 1999-07-30 2007-02-20 Large Scale Biology Corporation Microarrays and their manufacture by slicing
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7208145B2 (en) 2002-12-31 2007-04-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
CA2525464A1 (en) 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
MXPA05012314A (es) 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
DK1625156T3 (da) 2003-05-12 2013-01-07 Affymax Inc Peptider, der bindes til erythropoietinreceptoren
PT1629007E (pt) 2003-05-12 2009-05-06 Affymax Inc Péptidos novos que se ligam ao receptor da eritropoietina
US7887789B2 (en) 2003-05-23 2011-02-15 Nektar Therapeutics Polymer derivatives having particular atom arrangements
EP2626083A1 (de) 2003-09-17 2013-08-14 Nektar Therapeutics Multi-Arm Polymerprodrogen
EA018427B1 (ru) 2003-12-16 2013-07-30 Нектар Терапьютикс Химически модифицированный налоксон
JP2007529475A (ja) * 2004-03-17 2007-10-25 アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 等比体積の形態変換
US9085659B2 (en) 2004-05-03 2015-07-21 Nektar Therapeutics Polymer derivatives comprising an imide branching point
US8562965B2 (en) 2004-05-03 2013-10-22 Nektar Therapeutics Polymer derivatives comprising an acetal or ketal branching point
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
CA2586915A1 (en) * 2004-11-10 2006-05-18 Aplagen Gmbh Molecules which promote hematopoiesis
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
EP1884235A1 (de) * 2005-04-26 2008-02-06 Ajinomoto Co., Inc. Die differenzierung myeloerythroider progenitorzellen induzierende substanz
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
JP2008546732A (ja) * 2005-06-23 2008-12-25 アプラゲン ゲーエムベーハー 多価化合物
CN101378772B (zh) * 2005-08-05 2013-12-04 阿拉伊姆药品公司 组织保护性肽及其用途
SG170086A1 (en) * 2006-03-09 2011-04-29 Aplagen Gmbh De Modified molecules which promote hematopoiesis
EP3669894A3 (de) 2006-06-30 2020-08-26 Syntab Therapeutics GmbH Neuartige multifunktionale verbindungen für pharmazeutische zwecke
EP2118127A4 (de) 2007-01-31 2010-12-01 Affymax Inc Linker auf stickstoffbasis zur bindung modifizierender gruppen an polypeptide und andere makromoleküle
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
CN101456911A (zh) * 2007-12-12 2009-06-17 江苏豪森药业股份有限公司 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
EP2268304A2 (de) * 2008-03-26 2011-01-05 Orthologic Corp. Verfahren zur behandlung akuter myokardinfarkte
WO2010014258A2 (en) 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
JP5588983B2 (ja) 2008-08-11 2014-09-10 ウェルズ ファーゴ バンク ナショナル アソシエイション マルチアームポリマーアルカノエートコンジュゲート
EP2331139B1 (de) 2008-09-11 2019-04-17 Nektar Therapeutics Polymer-alpha-hydroxy-aldehyd und keton-reagenzien und konjugationsverfahren
AU2009292643B2 (en) 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
US8278418B2 (en) * 2008-09-26 2012-10-02 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
JP6059014B2 (ja) * 2009-06-19 2017-01-11 アリゾナ ボード オブ リージェンツ ア ボディー コーポレート アクティング オン ビハーフ オブ アリゾナ ステイト ユニバーシティＡＲＩＺＯＮＡ ＢＯＡＲＤ ＯＦ ＲＥＧＥＮＴＳ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ ａｃｔｉｎｇ ｏｎ ｂｅｈａｌｆ ｏｆ ＡＲＩＺＯＮＡ ＳＴＡＴＥ ＵＮＩＶＥＲＳＩＴＹ 試料の構成成分の検出において使用されるデバイスを製造する方法およびペプチドアレイ
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
DK2590666T3 (en) 2010-07-06 2017-07-17 Augustinus Bader TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
WO2013171810A1 (ja) 2012-05-14 2013-11-21 パナソニック株式会社 耐熱性抗体提示ファージを得る方法
CN103450348B (zh) * 2012-05-29 2016-03-30 中国人民解放军军事医学科学院毒物药物研究所 一种促红细胞生成素模拟肽、其制备方法和用途
CN106608906A (zh) * 2015-10-22 2017-05-03 天津药物研究院有限公司 一种具有刺激红细胞生成功能的环形多肽的制备及其应用
CN106928338A (zh) * 2015-12-31 2017-07-07 杭州阿德莱诺泰制药技术有限公司 促红细胞生成素肽及衍生物和聚合物、制备方法和应用
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
US12024571B2 (en) 2018-09-14 2024-07-02 Epo-Med Inc. Anti-erythropoietin receptor peptide
US20220296521A1 (en) 2019-06-10 2022-09-22 Respira Therapeutics, Inc. Carrier-based formulations and related methods
WO2025262329A1 (en) 2024-06-21 2025-12-26 Syntab Therapeutics Gmbh Synthetic molecules comprising tlr2 ligands

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
WO1990008822A1 (en) * 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers

Also Published As

Publication number Publication date
NO975729L (no) 1998-02-05
JPH11507367A (ja) 1999-06-29
JP2007277264A (ja) 2007-10-25
EP0886648B1 (de) 2003-11-12
EP1510524A2 (de) 2005-03-02
KR19990022656A (ko) 1999-03-25
PL323858A1 (en) 1998-04-27
JP2009280616A (ja) 2009-12-03
EP1510524A3 (de) 2006-06-07
DE69630708D1 (de) 2003-12-18
ES2210374T3 (es) 2004-07-01
CZ391097A3 (cs) 1998-07-15
TR199701557T2 (xx) 2002-06-21
CN1192748A (zh) 1998-09-09
CA2223833C (en) 2010-12-21
IL122417A0 (en) 1998-06-15
CA2223833A1 (en) 1996-12-19
BR9609006A (pt) 1999-12-14
HUP9901069A2 (hu) 1999-07-28
AU712713B2 (en) 1999-11-11
AU6166796A (en) 1996-12-30
DE69630708T2 (de) 2004-08-05
EP0886648A4 (de) 2000-01-12
KR100459984B1 (ko) 2005-06-20
EP0886648B8 (de) 2004-03-03
NO318783B1 (no) 2005-05-09
JP4050314B2 (ja) 2008-02-20
EP0886648A1 (de) 1998-12-30
PL185040B1 (pl) 2003-02-28
NZ310804A (en) 1998-10-28
WO1996040749A1 (en) 1996-12-19
NO975729D0 (no) 1997-12-05

Similar Documents

Publication Publication Date Title
DE69630708D1 (de) An den erythropoietin-rezeptor bindende zusammensetzungen und peptide
DK0794961T3 (da) LHRH-antagonistpeptider
ATE134647T1 (de) Osteogene vorrichtungen
DE69735580D1 (de) An aminosaeure angereicherte speicherproteine, insbesondere an lysin angereicherte mais-gamma-zeine, und diese exprimierende pflanzen
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
GB9720054D0 (en) Biological products
CA2094027A1 (en) Osteogenic peptides
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
DE69929454D1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
SE9602822D0 (sv) New receptor
ATE294816T1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
ATE93527T1 (de) Peptide und deren benutzung.
DE69315730D1 (de) Verfahren zur Herstellung von Peptiden und neue Zwischenverbindungen dazu
DK1342729T3 (da) Antistoffer og antisense-molekyler for G-koblet receptor der udviser selektiv affinitet for ATP
WO2000000506A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
PT959895E (pt) Peptidos que reajem a anticorpos contra um peptido de consenso da familia de proteinas cs4-cfa/i
SE9604439D0 (sv) New receptor
GB9604518D0 (en) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties